KAIROS PHARMA, LTD. Net Change in Cash
KAIROS PHARMA, LTD. (KAPA) reported Net Change in Cash of -$1.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$816.00K, a 134.81% decline year-over-year.
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $2.34M.
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$53.00K.
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $3.22M, a 173.03% increase from fiscal 2024.
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $1.18M.
- KAIROS PHARMA, LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$344.00K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.86M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$816.00K 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $3.22M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $4.30M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.76M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $2.34M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $1.18M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $3.12M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$72.00K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$53.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$344.00K 10-K · filed 2025-04-15 | |||
| 2023-09-30 | -$338.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |